Biomea Fusion Inc (BMEA) Stock Price, Quote & News

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 980 9099

Website: biomeafusion.com

Address:

1599 Industrial Road, San Carlos, United States

Mr_GA Dec. 25 at 2:02 PM

$BMEA

0 · Reply

Jacksandknaves Dec. 24 at 10:53 PM

$BMEA $MLTX how much are you down here ?

1 · Reply

Eternal_Optimist Dec. 24 at 9:27 PM

$BMEA Happy Holidays and Merry Christmas to ALL! I purchased another 5,000 shares today for 80,000 overall. Ultimately this is a push and pull between longs and shorts. That’s healthy and the very active and passionate forum is great also. It comes down to whether or not the individual/retail investor and for that matter the institutional investors believe in successful outcomes for the Phase 2 Covalent 211/2 studies that IMHO will continue to help refine the “product market fit” for BMF-219 (Icovamenib) in severely insulin deficient patients and those failing glycemic control with GLP-1 therapy. The food effects study will hopefully supercharge those studies by finding the right timing for drug administration related to food. We will also see how BMF-650 performs in Phase 1 by mid next year. Big Pharma likely wants to see further de risking by seeing success in the above studies by mid next year (Phase 2). The company appears to have raised sufficient capital to complete this!

1 · Reply

Jacksandknaves Dec. 24 at 8:06 PM

$BMEA $MLTX how much you down on this play ?

4 · Reply

Apes_Strong Dec. 24 at 5:57 PM

$BMEA taken !!! Excellent

0 · Reply

Apes_Strong Dec. 24 at 5:47 PM

$BMEA someone just dumped 75,000 shares and offering another 30,000 at 1.27 If that gets taken a good sign

0 · Reply

Pedross Dec. 24 at 5:45 PM

$BMEA This stock is controlled by short sellers. Until some positive news or data, we are at their mercy. A sell of the oncology or a Big Pharma partnership is the only way to bring back buyers and push short to cover. Retail traders can't do nothing but sit down and watch, it's up to management to deliver for the shareholders.

0 · Reply

Creisi Dec. 24 at 4:55 PM

$MLTX $BMEA Before I check out today, I want to answer one last question I received lately. Why do I battle shorts on specific stocks like $BMEA & $MLTX ? Well, I came from clinical biopharma and funding is a 24 hour a day task. There are many really good medicines being developed and there are some which are not. The bad ones, in my opinion, are fair game for shorts. The good ones are not. I am determined to ensure companies with solid science developing much needed medicines acheive their goal of helping millions in need. Many companies in CB are started by folks determined to make people happier. They are the only thing advancing medicine for everyone. Without them there would be far more injury, disease & epidemics. Many folks would die. These companies are the life line of our most precious commodity. Our health. Nothing on this planet is more important. I wish everyone a healthy and warm Christmas Holiday & a prosperous and caring 2026! Merry Christmas Everyone!

8 · Reply

Martincircus Dec. 24 at 4:19 PM

$BMEA I'm not for idol worship celebrations... It was originally a festival of idolatry... which today has transformed into a commercial and culinary celebration. I have nothing to do with this thing.

2 · Reply

Bigbadjohn89 Dec. 24 at 3:47 PM

$BMEA $MLTX look at how much they have lost hahahaha

1 · Reply

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 6:35 PM EST - 15 days ago

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Dec 5, 2025, 7:00 AM EST - 20 days ago

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 1, 2025, 4:10 PM EST - 23 days ago

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 1, 2025, 4:05 PM EST - 23 days ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Nov 24, 2025, 7:00 AM EST - 4 weeks ago

Biomea Fusion to Participate at Upcoming Investor Conferences

Nov 10, 2025, 7:00 AM EST - 6 weeks ago

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Nov 5, 2025, 7:00 AM EST - 7 weeks ago

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

Nov 4, 2025, 4:05 PM EST - 7 weeks ago

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Oct 30, 2025, 8:00 AM EDT - 2 months ago

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Oct 27, 2025, 8:00 AM EDT - 2 months ago

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Oct 23, 2025, 3:57 PM EDT - 2 months ago

Biomea Fusion, Inc. (BMEA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript

Oct 21, 2025, 7:05 PM EDT - 2 months ago

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Oct 7, 2025, 12:05 PM EDT - 2 months ago

Biomea Fusion, Inc. - Special Call

Oct 7, 2025, 10:35 AM EDT - 2 months ago

Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study

Oct 7, 2025, 8:00 AM EDT - 2 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities

Oct 6, 2025, 4:18 PM EDT - 2 months ago

Biomea Fusion Announces Proposed Public Offering of Securities

Oct 6, 2025, 4:03 PM EDT - 2 months ago

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Oct 1, 2025, 7:00 AM EDT - 3 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Sep 16, 2025, 7:00 AM EDT - 3 months ago

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Aug 5, 2025, 4:05 PM EDT - 5 months ago

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Jul 24, 2025, 7:00 AM EDT - 5 months ago

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Jun 23, 2025, 7:00 AM EDT - 6 months ago

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 7:00 AM EDT - 6 months ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 18, 2025, 6:28 AM EDT - 6 months ago

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Jun 17, 2025, 7:28 PM EDT - 6 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR

$Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025$

Jun 13, 2025, 6:45 AM EDT - 6 months ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

$Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia$

May 14, 2025, 4:05 PM EDT - 8 months ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 5, 2025, 4:05 PM EDT - 8 months ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 4:01 PM EDT - 9 months ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 4:10 PM EDT - 9 months ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 25, 2025, 7:00 PM EDT - 9 months ago

Biomea Fusion Announces Leadership Transition

Mar 24, 2025, 8:30 AM EDT - 9 months ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Feb 27, 2025, 8:00 AM EST - 10 months ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Dec 17, 2024, 10:41 AM EST - 1 year ago

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Dec 17, 2024, 8:10 AM EST - 1 year ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 16, 2024, 6:15 PM EST - 1 year ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 12, 2024, 5:02 PM EST - 1 year ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

$Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia$

Dec 9, 2024, 4:01 PM EST - 1 year ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

$Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia$

Dec 6, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Nov 3, 2024, 11:00 AM EST - 1 year ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 1 year ago

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 30, 2024, 4:00 PM EDT - 1 year ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Oct 29, 2024, 4:46 PM EDT - 1 year ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 29, 2024, 11:00 AM EDT - 1 year ago

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Mr_GA Dec. 25 at 2:02 PM

$BMEA

0 · Reply

Jacksandknaves Dec. 24 at 10:53 PM

$BMEA $MLTX how much are you down here ?

1 · Reply

Eternal_Optimist Dec. 24 at 9:27 PM

1 · Reply

Jacksandknaves Dec. 24 at 8:06 PM

$BMEA $MLTX how much you down on this play ?

4 · Reply

Apes_Strong Dec. 24 at 5:57 PM

$BMEA taken !!! Excellent

0 · Reply

Apes_Strong Dec. 24 at 5:47 PM

$BMEA someone just dumped 75,000 shares and offering another 30,000 at 1.27 If that gets taken a good sign

0 · Reply

Pedross Dec. 24 at 5:45 PM

0 · Reply

Creisi Dec. 24 at 4:55 PM

8 · Reply

Martincircus Dec. 24 at 4:19 PM

2 · Reply

Bigbadjohn89 Dec. 24 at 3:47 PM

$BMEA $MLTX look at how much they have lost hahahaha

1 · Reply

Creisi Dec. 24 at 3:46 PM

$BMEA $MLTX Here's the pattern. Open account, attack me, get exposed, get banned or close account, open new account and repeat! SHORTS ARE REALLY ANGRY ABOUT MLTX! Did I get this right troll?

2 · Reply

Creisi Dec. 24 at 3:41 PM

$BMEA $MLTX you are angry. Hope you have a Christmas to match you personality. Bye.

1 · Reply

Martincircus Dec. 24 at 3:39 PM

$BMEA Have you noticed that Creisi only posts here now to insult people? Just two weeks ago he was raving about Biomea. Now, not a word. That little rat probably sold everything. He spots opportunities, encourages everyone to buy to hype things up, and then he disappears like a coward. Il va certainement faire pareil avec $MLTX 😄😄🤣🤣🤣⁉️⁉️⁉️

3 · Reply

G_Ho Dec. 24 at 3:38 PM

$BMEA $MLTX who knew we'd get some fireworks on Christmas Eve? Love it! Cheers and Happy Holidays to all 🍻

0 · Reply

Creisi Dec. 24 at 3:36 PM

$BMEA $MLTX Really, so which little shorting troll were you so Stock Wots can do it again. BTW I didn't get anyone disabled; that's not something I would do but thankfully someone else did. If you got disabled once, it won't be long before yo're disabled again. Just keep it up.

0 · Reply

Martincircus Dec. 24 at 3:36 PM

$BMEA simply because Some jerk deactivated my previous account. It might even be you, who knows?

0 · Reply

Creisi Dec. 24 at 3:31 PM

$BMEA $MLTX BULLSHIT. Your account was opened Dec 23/2025 and you immediately start attacking me... Gee a wonder why I was the target. Go away, no one on here is dumb enough to listen to you.

0 · Reply

Creisi Dec. 24 at 3:27 PM

$BMEA $MLTX Where the fuck did you come from. Your account was opened yesterday and today you're accusing me of something from 3 weeks ago. I smell bullshitter!

2 · Reply

Martincircus Dec. 24 at 3:18 PM

$MLTX i'm not shorting mltx, not at all. I has a few thousands shares, which i just sold today. I bought Biomea with that money. Good luck with mltx. That's a great opportunity to be honnest, but $BMEA might be the opportunity of the century. Think about it, a pharma with a cure for diabetes AND obesity (without loss of lean mass)

1 · Reply

Martincircus Dec. 24 at 3:17 PM

I'm not shorting mltx, not at all. I has a few thousands shares, which i just sold today. I bought Biomea with that money. Good luck with mltx. That's a great opportunity to be honnest, but $BMEA might be the opportunity of the century. Think about it, a pharma with a cure for diabetes and obesity (without loss of lean mass)

0 · Reply

Creisi Dec. 24 at 3:15 PM

$BMEA $MLTX I updated the following Tuesday. Go back and read it.

1 · Reply

Martincircus Dec. 24 at 12:21 PM

$BMEA still waiting on the update you had promised last december 7th regarding a biomea partnership with a big pharma... All this confirms you're a world class pumper. $MLTX share holders, you are warned. Being too naive might sometimes cause little probd

4 · Reply

Market Cap	89.79M
Revenue (ttm)	0.00
Net Income (ttm)	-138.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	492,900
Avg Vol	1,522,778
Day's Range	N/A - N/A
Shares Out	70.70M
Stochastic %K	14%
Beta	-0.14
Analysts	Strong Sell
Price Target	$7.00